Down-regulation of expression of interleukin-6 and its receptor results in growth inhibition of MCF-7 breast cancer cells.

Interleukin-6 (IL-6) plays an important role in the neoplastic process through its action on cancer cell adhesion, motility, proliferation, tumor-specific antigen expression, and thrombopoiesis. IL-6 exerts its activity by binding to a high affinity receptor complex consisting of two membrane glycoproteins: the 80 kDa IL-6 a-receptor subunit (IL-6R) and the 130 kDa signal-transducing protein (GP130). In the present study, MCF-7 breast cancer cells were cultured with human IL-6 and IL-6 soluble receptor (sIL-6R). MCF-7 cells were also treated with either antibodies specific to human IL-6 and IL-6R, or synthetic antisense oligodeoxynucleotides (ODNs) targeted to IL-6 and IL-6R genes. Cell growth was measured, and it was found that human IL-6 and sIL-6R did not significantly increase the proliferation of MCF-7 cells. When IL-6 produced by the MCF-7 cells was bound by rabbit anti-human IL-6 antibody, there was a significant dose-dependent inhibition of cell proliferation. IL-6 and IL-6R antisense ODNs caused a marked and specific decrease in IL-6 and IL-6R mRNA and proteins, respectively. Both IL-6 and IL-6R antisense ODNs significantly inhibited the proliferation of MCF-7 cells, but the inhibitory effect of IL-6R antisense ODN was greater than that of IL-6 antisense ODN (IC₅₀: IL-6R: 1 μM; IL-6: 5 μM, 72-hour incubation). Addition of exogenous IL-6 partially reversed the growth inhibition caused by IL-6 antisense ODN but not the growth inhibition caused by IL-6R antisense ODN. In conclusion, IL-6 plays an important role in maintaining the growth of MCF-7 breast cancer cells. These results suggest careful modulation of IL-6 and IL-6R expression of cells as a potential approach for breast cancer therapy.

[1]  J. Blay,et al.  Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. , 1992, Cancer research.

[2]  P. Sehgal,et al.  Interleukin-6 and 12-O-tetradecanoyl phorbol-13-acetate act synergistically in inducing cell-cell separation and migration of human breast carcinoma cells. , 1991, Cytokine.

[3]  T. Hirano,et al.  STAT3 orchestrates contradictory signals in cytokine‐induced G1 to S cell‐cycle transition , 1998, The EMBO journal.

[4]  V. Syed,et al.  Curcumin suppresses constitutive activation of STAT‐3 by up‐regulating protein inhibitor of activated STAT‐3 (PIAS‐3) in ovarian and endometrial cancer cells , 2010, Journal of cellular biochemistry.

[5]  T. Kishimoto,et al.  The biology of interleukin-6. , 1989, Blood.

[6]  R. Kyle,et al.  Prognostic factors in multiple myeloma , 1988, Hematological oncology.

[7]  C. Peschle,et al.  Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. , 1995, British Journal of Cancer.

[8]  N. Hynes,et al.  Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. , 2001, Cancer research.

[9]  T. Hirano,et al.  Structural and functional studies on the human hepatic interleukin-6 receptor. Molecular cloning and overexpression in HepG2 cells. , 1991, The Biochemical journal.

[10]  N. Iizuka,et al.  Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. , 1996, Cancer research.

[11]  E. Gehan,et al.  Prognostic factors in multiple myeloma , 1975, Cancer.

[12]  T. Hirano,et al.  Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130 , 1989, Cell.

[13]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[14]  U. Klingmüller,et al.  Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1 , 1999, Oncogene.

[15]  T. Hirano,et al.  Structure and expression of human B cell stimulatory factor‐2 (BSF‐2/IL‐6) gene. , 1987, The EMBO journal.

[16]  T. Okai,et al.  The influence of inflammatory cytokines on estrogen production and cell proliferation in human breast cancer cells. , 2002, Endocrine journal.

[17]  R. Kerbel,et al.  Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression [published erratum appears in J Cell Biol 1993 Apr;121(2):following 477] , 1993, The Journal of cell biology.

[18]  B. Kim,et al.  Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells , 2008, Molecular oncology.

[19]  T. Wheeler,et al.  Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. , 2002, The Journal of urology.

[20]  T. Hirano,et al.  Molecular basis underlying functional pleiotropy of cytokines and growth factors. , 1999, Biochemical and biophysical research communications.

[21]  J. Horiguchi,et al.  Changes of cytokines and thyroid function in patients with recurrent breast cancer. , 1997, Anticancer research.

[22]  M. Sgagias,et al.  Interleukin-1α and Interleukin-6 Act Additively to Inhibit Growth of MCF-7 Breast Cancer Cells in Vitro , 1993 .

[23]  E. Srivatsan,et al.  Suppression of interleukin 6 and 8 production in head and neck cancer cells with curcumin via inhibition of Ikappa beta kinase. , 2009, Archives of otolaryngology--head & neck surgery.

[24]  D. Fuchs,et al.  Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. , 2003, The American journal of pathology.

[25]  M. Oya,et al.  STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P. , 2002, Kidney international.

[26]  T. Hirano,et al.  A central role for Stat3 in IL‐6‐induced regulation of growth and differentiation in M1 leukemia cells. , 1996, The EMBO journal.

[27]  R. Elliott,et al.  Reduction in serum IL-6 after vacination of breast cancer patients with tumour-associated antigens is related to estrogen receptor status. , 2000, Cytokine.

[28]  Ya-Li Zhang,et al.  Tumor growth inhibition effect of hIL-6 on colon cancer cells transfected with the target gene by retroviral vector. , 2000, World journal of gastroenterology.

[29]  K. Yasukawa,et al.  Soluble interleukin-6 (IL-6) receptor with IL-6 stimulates megakaryopoiesis from human CD34(+) cells through glycoprotein (gp)130 signaling. , 1999, Blood.

[30]  A. Hoeflich,et al.  Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. , 2000, Cancer letters.

[31]  T. Hirano,et al.  Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. , 1996, Immunity.

[32]  R. Kurzrock,et al.  Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease. , 1997, The American journal of medicine.

[33]  J. Schlom,et al.  Interleukin-6 increases carcinoembryonic antigen and histocompatibility leukocyte antigen expression on the surface of human colorectal carcinoma cells. , 1992, Journal of immunotherapy.

[34]  E. Tartour,et al.  IL-6 is a survival prognostic factor in renal cell carcinoma. , 1997, Immunology letters.

[35]  T. Nakatani,et al.  Interleukin-6, tumour necrosis factor α and interleukin-1β in patients with renal cell carcinoma , 2002, British Journal of Cancer.

[36]  D. Weaver,et al.  Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. , 2001, Cancer research.

[37]  M. Corada,et al.  Monoclonal antibodies directed to different regions of vascular endothelial cadherin extracellular domain affect adhesion and clustering of the protein and modulate endothelial permeability. , 2001, Blood.

[38]  Hongyu Zhou,et al.  The targets of curcumin. , 2011, Current drug targets.

[39]  K. Yasukawa,et al.  Signal through gp130 Activated by Soluble Interleukin (IL)‐6 Receptor (R) and IL‐6 or IL‐6R/IL‐6 Fusion Protein Enhances Ex Vivo Expansion of Human Peripheral Blood‐Derived Hematopoietic Progenitors , 2000, Stem cells.

[40]  E. Keller,et al.  Effect of IL-6 receptor antisense oligodeoxynucleotide on in vitro proliferation of myeloma cells. , 1995, Journal of immunology.

[41]  Shiu-Feng Huang,et al.  Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways , 2003, Oncogene.

[42]  R. Drummond,et al.  Stimulation of megakaryocytopoiesis in mice by human recombinant interleukin-6. , 1991, Blood.

[43]  A. Hoffbrand,et al.  Interleukin-6 inhibits apoptosis and tumour necrosis factor induced proliferation of B-chronic lymphocytic leukaemia. , 1996, Leukemia & lymphoma.

[44]  V. Fontaine,et al.  Interferon-y and interleukin-6 inhibit proliferation in human melanoma cells by different signalling pathways , 1998, Melanoma research.

[45]  H. Redmond,et al.  Interleukin-6 upregulates GP96 expression in breast cancer. , 1997, The Journal of surgical research.

[46]  C. Kainz,et al.  Serum evaluation of interleukin 6 in ovarian cancer patients. , 1997, Gynecologic oncology.